Abstract
The human JAK2 gene is mainly targeted by two types of genetic lesions that play roles in the pathogenesis of hematologic malignancies: intragenic mutations and chromosomal translocations. Chromosomal translocations of JAK2 are typically associated with myeloid or lymphoid malignancies with an aggressive course and poor outcome. Here we report a t(9;22)(p24;q11.2) translocation, in a MDS patient and review results associated with BCR-JAK2 fusion reported in the literature.
Similar content being viewed by others
References
Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol. 2008;39(6):795–810.
Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008;49(3):388–97.
Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008;22(7):1320–34.
Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014;166:809–17.
Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44(3):329–33.
Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, et al. A BCR-JAK2 fusion gene as the result of a t(9;22) (p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183(2):105–8.
Lane SW, Fairbairn DJ, McCarthy C, Nandini A, Perry-Keene J, Kennedy GA. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22)(p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol. 2008;142(4):503.
Impera L, Lonoce A, Fanfulla DA, Moreilhon C, Legros L, Raynaud S. Two alternatively spliced 5′BCR/3′JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22) (p23;p11.3;q11.2) translocation. Cancer Genet. 2011;204:512–5.
Angelova S, Spassova S, Toshkov S, Shivarov V. Chromosomal translocation t(9;22) (p24;q11) appears to be recurrently associated with myeloid malignancy with aggressive course. Leuk Lymphoma. 2011;52(9):1809–10.
Elnaggar MM, Agersborg S, Sahoo T, Girgin A, Ma W, Rakkhit R, et al. BCR-JAK2 fusion as a result of a translocation (9;22) (p24;q11.2) in a patient with CML-like myeloproliferative disease. Mol Cytogenet. 2012;5(1):23.
Xu Y, Yin J, Pan J, Wu C, Wang Q, Yao H, et al. A BCR-JAK2 fusion gene from ins(22;9) (q11;p13p24) in a patient with atypical chronic myeloid leukemia. Leuk Lymphoma. 2013;54(10):2322–4.
Bellesso M, Santucci R, Dias DF, Centrone R, Elias RC. Atypical chronic myeloid leukemia with t(9;22) (p24,11.2), a BCR-JAK2 fusion gene. Rev Bras Hematol Hemoter. 2013;35:218–9.
Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94:233–8.
Tirado CA, Chen W, Huang LJ, Laborde C, Hiemenz MC, Valdez F, et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res. 2010;34(12):1674–6.
Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, et al. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One. 2012;7(2):e32451.
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153–66.
Chase A, Bryant C, Score J, Haferlach C, Grossmann V, Schwaab J, et al. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica. 2013;98(3):404–8.
Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9) (p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120(7):1529–31.
Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31(17):e269–71.
Conflict of interest
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kantarcioglu, B., Kaygusuz-Atagunduz, I., Uzay, A. et al. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. Int J Hematol 102, 383–387 (2015). https://doi.org/10.1007/s12185-015-1792-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-015-1792-2